Pfizer Wins Dismissal Of Securities Suit Over Drug

Law360, New York (February 28, 2008, 12:00 AM EST) -- In a boost to Pfizer Inc., a federal judge has granted the drug giant's bid to toss the amended complaint in a securities fraud lawsuit brought by investors over the company's decision to scrap its highly anticipated cholesterol drug torcetrapib.

Pfizer's knowledge that evidence of torcetrapib’s efficacy was inconclusive did not support an inference that its optimistic statements were materially misleading, Judge Lewis A. Kaplan of the U.S. District Court for the Southern District of New York said Thursday.

“Defendants were entitled to take an optimistic...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.